The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer

NACompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

December 20, 2019

Study Completion Date

December 31, 2019

Conditions
Prostate Cancer Recurrent
Interventions
DRUG

Degarelix 120 MG [Firmagon]

Two doses of degarelix, 240 mg, subcutaneously once, at study start.

DRUG

Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector

Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.

DRUG

Testosterone Undecanoate

One dose 1000 mg testosterone once, after 3 weeks.

Trial Locations (1)

21428

Reproductive Medicine Center, Malmo

All Listed Sponsors
collaborator

Swedish Cancer Foundation

OTHER

collaborator

ALF Swedish Government Grant

UNKNOWN

lead

Lund University

OTHER

NCT04134130 - The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer | Biotech Hunter | Biotech Hunter